U.S. Markets closed

Aytu Biopharma, Inc. (AYTU)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.48-0.17 (-3.01%)
At close: 4:00PM EDT
5.46 -0.02 (-0.36%)
After hours: 06:54PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.65
Bid5.44 x 1200
Ask5.49 x 1100
Day's Range5.38 - 5.70
52 Week Range4.73 - 17.00
Avg. Volume860,062
Market Cap137.935M
Beta (5Y Monthly)-0.29
PE Ratio (TTM)N/A
EPS (TTM)-3.10
Earnings DateMay 12, 2021 - May 17, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.25
  • 2 “Strong Buy” Stocks Trading at Rock-Bottom Prices

    2 “Strong Buy” Stocks Trading at Rock-Bottom Prices

    We’re halfway through the year, and while the markets have been volatile, investors are having a good time so far. The S&P 500 has gained 11% year-to-date, and the tech-heavy NASDAQ has gained 9%. With the Fed keeping interest rates at historic lows, stocks are offering better rates of return – and they are keeping ahead of inflation, as well. But while the overall markets are up, individual stock performance can and will vary. Which means that in the midst of a general rising trend, it’s still


    Aytu BioPharma to Present at Upcoming June Investor Conferences

    ENGLEWOOD, CO / ACCESSWIRE / May 25, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that Josh Disbrow, Chairman and Chief Executive Officer, will present at two upcoming investor conferences in June: * Jefferies Global Healthcare Conference: A live virtual presentation will occur on Tuesday, June 1, 2021 at 3:30 p.


    Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights

    \- Closed merger with Neos Therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company -\- Added late-stage pediatric onset rare disease asset, protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) to development pipeline -\- Record quarter for consumer health division with revenue reaching $8.4 million and Rx division revenue up 9% over same quarter last year -\- Grew leadership team with three executives including CFO, Rich Eisenstadt - \- Management to host live conference call and webcast today at 4:30 p.